Compare iShares MSCI South Korea ETF (EWY) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? iShares MSCI South Korea ETF trades at $148.83 (market cap $24.38B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: iShares MSCI South Korea ETF is far larger — about 2.9× Hinge Health Inc. Class A Common Stock's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 48 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| EWY | HNGE | |
|---|---|---|
Market Cap | $24.38B | $8.48B |
Volume | 22,329,675 | 879,799 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $105.14 |
52-Week Low | $85.17 | $31.17 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $8.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, is trading at $166.56, down 2.16% amid bearish technical signals. The ETF faces pressure from rising US yields and oil prices impacting South Korean tech stocks, though corporate earnings remain resilient with strong AI memory demand driving performance. Technical indicators show oversold conditions with RSI at 21.77 suggesting potential bounce.
Outlook remains cautious due to concentrated exposure to Samsung and SK hynix, making EWY highly sensitive to semiconductor cycle volatility. While AI infrastructure spending provides growth catalyst, macroeconomic headwinds and profit-taking near 7,000 KOSPI level present near-term risks for investors.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
